OCX logo

OncoCyte (OCX) EBITDA

Annual EBITDA

-$23.12 M
-$9.81 M-73.74%

December 31, 2023

Summary

Performance

1-Year Change

-73.74%

3-Year Change

+24.29%

5-Year Change

-57.91%

15-Year Change

-24.46%

OCX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

49.36%
OCX annual EBITDA is higher than 49.36% of companies in Healthcare sector

High & Low

All-time High

-$3.22 M

3-Year Low

-$48.46 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
OCX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Apr 11, 2025
OCX next annual earnings announcement is scheduled for Apr 11, 2025

OtherOCXprofitabilitymetrics:

Annual Revenue

$1.50 M
OCX annual revenue is $1.50 million

Annual Net Income

-$27.78 M
OCX annual net profit is -$27.78 million

Annual EBIT

-$24.80 M
OCX annual earnings before interest & taxes is -$24.80 million

Annual EPS

-$3.75
OCX annual earnings per share is -$3.75

Quarterly EBITDA

-$13.12 M
-$8.93 M-212.73%

September 30, 2024

Summary

Performance

3-Month Change

-212.73%

1-Year Change

-116.93%

3-Year Change

-101.85%

5-Year Change

-101.85%

OCX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

30.31%
OCX quarterly EBITDA is higher than 30.31% of companies in Healthcare sector

High & Low

All-time High

$6.44 M
OCX quarterly EBITDA is currently -303.69% below its historical high of $6.44 million

3-Year Low

-$15.65 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
OCX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Apr 11, 2025
OCX next earnings announcement is scheduled for Apr 11, 2025

OtherOCXprofitabilitymetrics:

Quarterly Revenue

$115.00 K
OCX quarterly revenue is $115.00 thousand

Quarterly Net Income

-$13.49 M
OCX quarterly net profit is -$13.49 million

Quarterly EBIT

-$13.46 M
OCX quarterly earnings before interest & taxes is -$13.46 million

Quarterly EPS

-$0.98
OCX quarterly earnings per share is -$0.98

TTM EBITDA

-$41.75 M
-$7.07 M-20.40%

September 30, 2024

Summary

Performance

3-Month Change

-20.4%

1-Year Change

-2102.06%

3-Year Change

-18.67%

5-Year Change

-18.67%

OCX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

35.35%
OCX TTM EBITDA is higher than 35.35% of companies in Healthcare sector

High & Low

All-time High

-$409.00 K

3-Year Low

-$48.46 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
OCX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Apr 11, 2025
OCX next earnings announcement is scheduled for Apr 11, 2025

OtherOCXprofitabilitymetrics:

TTM Revenue

$709.00 K
OCX TTM revenue is $709.00 thousand

TTM Net Income

-$43.14 M
OCX TTM net profit is -$43.14 million

TTM EBIT

-$43.08 M
OCX TTM earnings before interest & taxes is -$43.08 million

TTM EPS

-$4.54
OCX TTM earnings per share is -$4.54

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$23.12 M
OCX annual EBITDA is -$23.12 million

Annual Net Income

-$27.78 M
OCX annual net profit is -$27.78 million

Annual Interest Expense

$52.00 K
OCX annual interest expense is $52.00 thousand

Annual Income Tax

-
OCX annual income tax value is unknown

Annual D&A

$1.68 M
OCX annual depreciation & amortization is $1.68 million

OCX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-73.7%-116.9%-2102.1%
3 y3 years+24.3%-101.8%-18.7%
5 y5 years-57.9%-101.8%-18.7%

OCX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-73.7%+52.3%-303.7%+16.2%<-9999.0%+13.8%
5 y5-year-73.7%+52.3%-303.7%+16.2%<-9999.0%+13.8%
alltimeall time-618.5%+52.3%-303.7%+16.2%<-9999.0%+13.8%

OncoCyte EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$13.12 M(+212.7%)
-$41.75 M(+20.4%)
Jun 2024
-
-$4.20 M(-52.2%)
-$34.68 M(-9.6%)
Mar 2024
-
-$8.78 M(-43.9%)
-$38.34 M(+65.8%)
Dec 2023
-$23.12 M(+73.7%)
-$15.65 M(+158.8%)
-$23.12 M(+1119.6%)
Sep 2023
-
-$6.05 M(-23.1%)
-$1.90 M(+7.1%)
Jun 2023
-
-$7.86 M(-222.0%)
-$1.77 M(+332.8%)
Mar 2023
-
$6.44 M(+15.6%)
-$409.00 K(-95.5%)
Dec 2022
-$13.31 M(-72.5%)
$5.57 M(-194.1%)
-$9.02 M(-68.5%)
Sep 2022
-
-$5.92 M(-8.9%)
-$28.60 M(-18.7%)
Jun 2022
-
-$6.50 M(+199.9%)
-$35.18 M(-11.2%)
Mar 2022
-
-$2.17 M(-84.5%)
-$39.64 M(-18.2%)
Dec 2021
-$48.46 M(+58.7%)
-$14.01 M(+12.0%)
-$48.46 M(+18.6%)
Sep 2021
-
-$12.51 M(+14.1%)
-$40.84 M(+20.3%)
Jun 2021
-
-$10.96 M(-0.3%)
-$33.96 M(+6.8%)
Mar 2021
-
-$10.99 M(+71.9%)
-$31.80 M(+8.2%)
Dec 2020
-$30.54 M(+39.5%)
-$6.39 M(+13.7%)
-$29.39 M(-3.5%)
Sep 2020
-
-$5.62 M(-36.1%)
-$30.45 M(+1.5%)
Jun 2020
-
-$8.79 M(+2.5%)
-$30.00 M(+12.9%)
Mar 2020
-
-$8.58 M(+15.1%)
-$26.58 M(+22.3%)
Dec 2019
-$21.89 M
-$7.45 M(+44.0%)
-$21.74 M(+19.3%)
DateAnnualQuarterlyTTM
Sep 2019
-
-$5.17 M(-3.8%)
-$18.21 M(+14.2%)
Jun 2019
-
-$5.38 M(+44.0%)
-$15.95 M(+9.0%)
Mar 2019
-
-$3.73 M(-4.9%)
-$14.64 M(+1.3%)
Dec 2018
-$14.64 M(-21.2%)
-$3.93 M(+34.8%)
-$14.46 M(+1.4%)
Sep 2018
-
-$2.91 M(-28.3%)
-$14.26 M(-20.9%)
Jun 2018
-
-$4.06 M(+14.3%)
-$18.03 M(+2.6%)
Mar 2018
-
-$3.55 M(-4.7%)
-$17.57 M(-5.4%)
Dec 2017
-$18.58 M(+72.8%)
-$3.73 M(-44.2%)
-$18.58 M(+4.1%)
Sep 2017
-
-$6.68 M(+85.5%)
-$17.84 M(+30.9%)
Jun 2017
-
-$3.60 M(-21.1%)
-$13.63 M(+9.4%)
Mar 2017
-
-$4.56 M(+52.6%)
-$12.46 M(+15.8%)
Dec 2016
-$10.75 M(+27.5%)
-$2.99 M(+20.9%)
-$10.75 M(-4.2%)
Sep 2016
-
-$2.47 M(+1.9%)
-$11.23 M(+1.2%)
Jun 2016
-
-$2.43 M(-15.1%)
-$11.09 M(+10.9%)
Mar 2016
-
-$2.86 M(-17.5%)
-$10.00 M(+18.6%)
Dec 2015
-$8.43 M(+79.3%)
-$3.47 M(+48.4%)
-$8.43 M(+31.7%)
Sep 2015
-
-$2.34 M(+75.0%)
-$6.40 M(+57.5%)
Jun 2015
-
-$1.33 M(+3.1%)
-$4.07 M(+48.9%)
Mar 2015
-
-$1.29 M(-9.8%)
-$2.73 M(+90.2%)
Dec 2014
-$4.70 M(+46.1%)
-$1.44 M
-$1.44 M
Dec 2013
-$3.22 M
-
-

FAQ

  • What is OncoCyte annual EBITDA?
  • What is the all time high annual EBITDA for OncoCyte?
  • What is OncoCyte annual EBITDA year-on-year change?
  • What is OncoCyte quarterly EBITDA?
  • What is the all time high quarterly EBITDA for OncoCyte?
  • What is OncoCyte quarterly EBITDA year-on-year change?
  • What is OncoCyte TTM EBITDA?
  • What is the all time high TTM EBITDA for OncoCyte?
  • What is OncoCyte TTM EBITDA year-on-year change?

What is OncoCyte annual EBITDA?

The current annual EBITDA of OCX is -$23.12 M

What is the all time high annual EBITDA for OncoCyte?

OncoCyte all-time high annual EBITDA is -$3.22 M

What is OncoCyte annual EBITDA year-on-year change?

Over the past year, OCX annual EBITDA has changed by -$9.81 M (-73.74%)

What is OncoCyte quarterly EBITDA?

The current quarterly EBITDA of OCX is -$13.12 M

What is the all time high quarterly EBITDA for OncoCyte?

OncoCyte all-time high quarterly EBITDA is $6.44 M

What is OncoCyte quarterly EBITDA year-on-year change?

Over the past year, OCX quarterly EBITDA has changed by -$7.07 M (-116.93%)

What is OncoCyte TTM EBITDA?

The current TTM EBITDA of OCX is -$41.75 M

What is the all time high TTM EBITDA for OncoCyte?

OncoCyte all-time high TTM EBITDA is -$409.00 K

What is OncoCyte TTM EBITDA year-on-year change?

Over the past year, OCX TTM EBITDA has changed by -$39.85 M (-2102.06%)